Rodger Macarthur, MD
Infectious Disease · Detroit, MINPI 1831137959
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,430 of the $150,354 with a category attached, or 71.5%. 11 manufacturers reported payments, led by Janssen Products, LP at 51.4% of the total. Reporting peaked in 2019 at $115,091 and has fallen 99.6% since, to $462 in 2024. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $621.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Products, LP$77K
- Viiv Healthcare Company$70K
- GSK$1K
- Gilead$846
- AbbVie$309
- Janssen Scientific Affairs, LLC$273
- plus $643 from 5 others
Across 7 payments — averaging $3453.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Emergent Biosolutions Inc.$24K
- Amgen$36
What the payments were for
- Consulting fees$9,2006%
- Speaking & faculty fees$107,43071%
- Travel & lodging$27,63418%
- Food & beverage$5,9194%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Products, LP | 77 | $77,298 |
| Viiv Healthcare Company | 71 | $69,822 |
| GSK | 9 | $1,163 |
| Gilead | 8 | $846 |
| AbbVie(2 entities) | 47 | $309 |
| Janssen Scientific Affairs, LLC | 4 | $273 |
| Johnson & Johnson | 14 | $266 |
| Merck | 7 | $131 |
| Angiodynamics, Inc. | 1 | $104 |
| Next Science LLC | 1 | $97 |
| Melinta Therapeutics, LLC | 3 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$150,354 in reported general payments places this provider in the 95th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 249 | $993,175 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 79 | $263,340 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 42 | $186,092 |
| DescovyEmtricitabine/Tenofov Alafenam | 71 | $143,794 |
| TivicayDolutegravir Sodium | 56 | $112,214 |
| PrezcobixDarunavir/Cobicistat | 48 | $105,318 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $65,030 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| IsentressRaltegravir Potassium | 22 | $44,015 |
| Darunavir | 11 | $17,432 |
| Etravirine | 13 | $16,017 |
| EntrestoSacubitril/Valsartan | 11 | $5,378 |
| Atazanavir Sulfate | 11 | $2,267 |
| Hydromorphone Hcl | 24 | $1,553 |
| Ritonavir | 23 | $1,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $846 | $1,184,992332 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato | $69,822 | $440,583157 claims |
| Janssen Products, LPSymtuza | $77,298 | $186,09242 claims |
| Johnson & JohnsonPrezcobix | $266 | $105,31848 claims |
| MerckIsentress | $131 | $44,01522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 infectious disease providers in Michigan.
Other infectious disease in Detroit
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Marcus ZervosDetroit$26K
- Jack SobelDetroit$18K
- Smitha GudipatiDetroit$16K
- Ronaldo SupenaDetroit$14K
- Wasif HafeezDetroit$5K
- Nicholas YaredDetroit$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.